Tempest Therapeutics, Inc. Material Event - What Happened

Think of this as a cheat sheet for what is happening at Tempest Therapeutics. We are cutting through the complex language to get to the heart of the news.

---

1. What happened?

On March 30, 2026, Tempest Therapeutics shared its 2025 financial results. The company is undergoing a major strategic pivot: moving away from a broad range of cancer treatments to focus exclusively on a specialized cell therapy model. Key updates include the acquisition of new cell therapy assets, the appointment of Dr. Matt Angel as CEO to lead this transition, and the release of promising early data for their lead drug, TPST-2003, which is currently being tested for patients with multiple myeloma.

2. Why does this matter?

Tempest is a clinical-stage biotech company, meaning it does not yet generate revenue from product sales. Its survival depends entirely on its "cash runway"—the amount of time it has before it runs out of capital.

• The Good News: In a small study of six patients, TPST-2003 showed a 100% response rate, with every patient seeing their cancer disappear. The company plans to initiate a major U.S. study in late 2026, a critical milestone toward potential FDA approval.
• The Reality Check: The company is running low on cash. Tempest ended 2025 with $7.7 million, a 75% decrease from the $30.3 million held at the end of 2024. To continue operations, the company must either secure a funding partner or issue more shares, which would dilute the value of your current holdings.

3. Who is affected?

• Investors: Shareholders face high risks. While the drug shows significant promise, the company’s low cash reserves are a major concern. Watch for announcements regarding potential stock sales or licensing deals, as these will directly impact your investment value.
• The Company: Under CEO Dr. Matt Angel, Tempest is cutting costs aggressively. They slashed research spending by 56% last year, dropping from $28.5 million to $12.6 million, and are now outsourcing non-essential work to preserve capital.
• Patients: TPST-2003 could be a breakthrough for multiple myeloma patients who have not responded to standard treatments. Notably, the drug has not yet shown the severe side effects often associated with similar therapies.

4. What should you know?

• The "Burn Rate": With only $7.7 million remaining, the company is spending money faster than it can sustain. They are actively pursuing "partner-funded" models, where larger pharmaceutical companies provide cash in exchange for a share of future profits.
• The Stock: Biotech stocks are inherently volatile. Because cash is low, the company may issue more shares to raise money. This dilutes your ownership and can lower the per-share value.
• The Strategy: By moving to a partnership-led model, Tempest hopes to extend its survival. While this is a necessary move, it means they will retain a smaller piece of the long-term profits from their drugs if they succeed.

5. What happens next?

The primary event to watch is the start of the U.S. study for TPST-2003 in late 2026. Success in this trial is essential for eventual FDA approval. In the meantime, keep a close eye on company filings for news about new partnerships or capital-raising efforts.

---

Investor Takeaway: Tempest is a high-risk, high-reward play. The clinical data is very encouraging, but the company’s financial position is precarious. If you are considering an investment, weigh the potential of their breakthrough drug against the high likelihood of further share dilution or the need for a dilutive partnership deal in the near future.